<DOC>
	<DOCNO>NCT02031991</DOCNO>
	<brief_summary>This study prove handling ( also refer pharmacokinetics ) follow drug PF-06439535 , Avastin® ( bevacizumab ) license use United States ( bevacizumab-US ) Avastin® ( bevacizumab ) obtain Europe ( bevacizumab-EU ) similar healthy male volunteer receive single intravenous dose either drug . During course study , similarity pharmacokinetics assess sampling level drug blood , compare level among different administration arm PF-06439535 , bevacizumab-US bevacizumab-EU . Safety , tolerability , immunologic response administer drug also evaluate throughout .</brief_summary>
	<brief_title>A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers ( REFLECTIONS B739-01 )</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Healthy male subject 2155 year old Subjects previously expose biologic agent ( VEGF [ Vascular Endothelial Growth Factor Receptor ] inhibitor ) may enroll provide least 3 month pass since last administration drug Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50kg ( 110lbs ) Evidence history clinically significant disease clinical find Screening Previous treatment antiVEGF antibody , antibody protein target VEGF receptor .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Biosimilarity</keyword>
	<keyword>Similarity</keyword>
	<keyword>PK</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Single-Dose</keyword>
	<keyword>Oncology</keyword>
</DOC>